50
OF 100
VENDOR AUDIT
Peptide Partners
32 Kovera vial reports at a 99.83% median purity, three Kovera fails its own ledger omits, and open FDA warning letter 735063. Public-data audit, 50/100.
affiliate disclosure · we earn commission on some vendor links. audits, scores, and rankings are independent — vendors do not pay for placement. read more →
VENDOR MATCHUP · AUDITED
Peptide Partners vs Summit Biotech
Two audits, side by side. Composite, subscores, shipping, payment, coupons. Summit Biotech takes the higher composite this cycle.
Composite score
vs
55
OF 100
VENDOR AUDIT
Summit Biotech
Operator received an FDA warning letter on December 10, 2024 as "Summit Research Peptides," then rebranded to Summit Biotech without disclosing the prior identity on the new site. Login-walled catalog, code-name SKUs for the FDA-cited compounds, and the cheapest per-mg pricing in our seven-vendor index on Tirzepatide, Retatrutide, and Semaglutide. ~90% of COAs are real Janoshik public-database links.
Subscore breakdown
7 METRICSMETRIC
PEPTIDE PARTNERS
SUMMIT BIOTECH
Composite · weighted avg
50/100
vs
55/100
Purity / COA
68/100
vs
70/100
Shipping · domestic days
4.0d
vs
5.0d
Pricing
78/100
vs
95/100
Support
45/100
vs
40/100
Last tested
2026-10-09
vs
2026-05-09
Payment
card, wire
vs
crypto, card
Catalog overlap
ONLY PEPTIDE PARTNERS
ss-31epitalon
BOTH
retatrutidetirzepatidesemaglutidebpc-157tb-500mots-ctesamorelinghk-cu
ONLY SUMMIT BIOTECH
cagrilintide